Singular Genomics Systems (Singular Genomics Systems) Debt-to-Asset : 0.28 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Singular Genomics Systems Debt-to-Asset?

Singular Genomics Systems's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $7.76 Mil. Singular Genomics Systems's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $67.52 Mil. Singular Genomics Systems's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was $265.47 Mil. Singular Genomics Systems's debt to asset for the quarter that ended in Dec. 2023 was 0.28.

Singular Genomics Systems Debt-to-Asset Historical Data

The historical data trend for Singular Genomics Systems's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Singular Genomics Systems Debt-to-Asset Chart

Singular Genomics Systems Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

0.05

0.31

0.03

0.18

0.28

Singular Genomics Systems Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Asset	Get a 7-Day Free Trial												0.18	0.19	0.21	0.27	0.28

Competitive Comparison of Singular Genomics Systems's Debt-to-Asset

For the Medical Instruments & Supplies subindustry, Singular Genomics Systems's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Singular Genomics Systems's Debt-to-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Singular Genomics Systems's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Singular Genomics Systems's Debt-to-Asset falls into.

Singular Genomics Systems Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Singular Genomics Systems's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(7.764	+	67.524)	/	265.467
	=	0.28

Singular Genomics Systems's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(7.764	+	67.524)	/	265.467
	=	0.28

Singular Genomics Systems (NAS:OMIC) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Singular Genomics Systems Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Singular Genomics Systems's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Singular Genomics Systems (Singular Genomics Systems) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Singular Genomics Systems Inc (NAS:OMIC) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

3010 Science Park Road, San Diego, CA, USA, 92121

Website

https://www.singulargenomics.com

Singular Genomics Systems Inc is a life science technology company that is leveraging novel next generation sequencing and multiomics technologies to build products that empower researchers and clinicians. The product development pipeline comprises two initial integrated solutions, each designed to leverage Sequencing Engine and purpose built to address different applications. The G4 Sequencing Platform is designed to target the NGS market. The PX Integrated Solution is designed to target the single cell, spatial analysis and proteomics markets. Both integrated solutions are used in many different and diverse market segments, including basic biology, oncology, immunology, neurology, genetic diseases, infectious diseases, the human microbiome and many others.

Executives

Andrew Spaventa	director, 10 percent owner, officer: Chief Executive Officer	10931 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Eli N. Glezer	officer: Chief Scientific Officer	10931 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Jyotsna Ghai	officer: Chief Operating Officer	3010 SCIENCE PARK ROAD, SAN DIEGO CA 92121
Kim P. Kamdar	director	C/O DOMAIN ASSOCIATES, L.L.C., ONE PALMER SQUARE, SUITE 515, PRINCETON NJ 08542
Marcia Eisenberg	director	C/O 908 DEVICES INC., 645 SUMMER STREET, BOSTON MA 02210
Sam Ropp	officer: Chief Commercial Officer	3010 SCIENCE PARK ROAD, SAN DIEGO CA 92121
Michael J Pellini	director	222 DUTTON MILL RD, WILLISTOWN PA 19380
Elaine R Mardis	director	301 MERRITT 7, NORWALK CT 06851
James E Flynn	10 percent owner, other: *Possible Member of 10% Group	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
David Daly	officer: President and Chief Operating	10931 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Vincent Brancaccio	officer: Vice President, HR	10931 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Dalen Meeter	officer: Vice President, Finance	10931 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Daralyn Durie	officer: General Counsel	10931 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Jorge Velarde	officer: Senior Vice President	10931 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
David L Barker	director	9885 TOWNE CENTRE DR, SAN DIEGO CA 92121